Our Approach

Until recently, scientists believed that mature adult cells were permanently locked into their differentiated state and unable to return to their pluripotent stem cell state and in 2006 this changed with the nobel prize winning discovery of IPS stem cells. Pluripotent stem cells are the only stem cells capable of creating new smooth muscle cells, endothelial cells and cardiomyocytes and can be manufactured in an unlimited fashion to create new muscle that starts to cure the underlying disease. 

After a heart attack, a person can lose billions of heart cells within minutes. Once lost, those cells are gone for good. As a result, many heart attack survivors must take medications that only address their symptoms and not restore heart function. IPS HEART's patented therapy actually creates new heart muscle cells that replace dead heart cells and restore cardiac function. Despite being the largest source of morbidity worldwide, current cardiac drugs or cardiac devices cannot create any new heart muscle and thus cannot improve heart function typically lost from a heart attack.

Using our small molecule IPS platform approach, we can also create new skeletal muscle with 100% full length human dystrophin that can be used in rare muscle diseases such as Duchenne Muscle Dystrophy as unfortunately DMD patients are confined to a wheelchair at ages 9-11 and have an early death with a median life expectancy of only 28 years. We believe transformative care that will extend life as well as taking DMD patients out of their wheel chairs should be the goal, not just myopically restoring a missing gene that cannot create any new skeletal muscle.